Humacyte(US:HUMA) Globenewswire·2025-07-23 12:00Core Insights - Humacyte, Inc. has announced the first sale of its product Symvess to a U.S. Military Treatment Facility, marking a significant milestone for the company in the defense healthcare sector [1][4] - The sale follows the recent approval of Symvess for listing on the Electronic Catalog (ECAT) by the U.S. Defense Logistics Agency, which allows access to military healthcare professionals [2][4] - Symvess is an acellular tissue engineered vessel that received FDA approval for use in extremity vascular trauma in December 2024, and is currently being developed for various other vascular applications [3][5] Company Overview - Humacyte, Inc. is focused on developing universally implantable bioengineered human tissues and advanced tissue constructs aimed at improving patient outcomes and transforming medical practices [5] - The company’s acellular tissue engineered vessel (ATEV) has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, highlighting its potential in treating vascular trauma and other conditions [5] - Humacyte is also engaged in late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease, as well as preclinical development for coronary artery bypass grafts and pediatric heart surgery [5]